Why I think these are the best ASX shares to buy and hold

I think these three market-leading businesses still have plenty of room to become much larger over the next decade.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Buying an ASX share is easy. Finding one I would be comfortable leaving alone for many years is much harder.

For a genuine buy-and-hold investment, I want a strong business today with plenty of opportunity still ahead.

These three could be best buys for me.

Woman and man at work looking at data on a tablet at work.

Image source: Getty Images

Pro Medicus Ltd (ASX: PME)

Pro Medicus is an ASX share that has already grown enormously, but I still think its best years could be ahead.

The healthcare technology company develops the Visage imaging platform used by hospitals and radiology groups to view and manage medical images.

Despite winning contracts with some of the United States' largest hospital networks, management has previously estimated that Pro Medicus still holds only around 11% of the market.

That leaves a substantial number of hospitals still available to win.

There is also more to the opportunity than radiology. Pro Medicus is expanding further into cardiology and broader enterprise imaging, potentially allowing its software to become more deeply embedded across hospital systems.

Winning major healthcare customers can take time, but once the platform becomes central to clinical workflows, I think those relationships can be extremely valuable.

That makes Pro Medicus the type of business I would be comfortable holding through short-term share price volatility.

TechnologyOne Ltd (ASX: TNE)

TechnologyOne could also be one of the best ASX shares for a long holding period.

Its enterprise software is used by councils, universities, government organisations, and other large institutions to manage important day-to-day operations.

These customers generally do not change core software systems lightly. Moving financial, payroll, property, or other critical processes to another provider can be expensive and disruptive. That helps TechnologyOne build long customer relationships and recurring revenue.

I also like that the business still has opportunities outside Australia. Its expansion in the United Kingdom gives TechnologyOne another sizeable market to pursue, while continued investment in cloud software and artificial intelligence could increase the value of its products for existing customers.

Overall, I think TechnologyOne has many of the qualities I want from an ASX share I would own for a decade or longer.

REA Group Ltd (ASX: REA)

REA Group is another ASX share I would be comfortable owning for the long term.

Its realestate.com.au platform has become deeply embedded in how Australians search for property, giving the company a very strong position with both buyers and sellers.

That large audience is a major advantage. Property agents want to advertise where buyers are already looking, while buyers keep returning because that is where the listings are. I think that creates a network effect that is difficult for competitors to replicate.

The Australian housing market will always move through stronger and weaker periods, so listings activity can fluctuate.

But over a long timeframe, I think REA Group's dominant position and ability to earn more from its audience give the business plenty of room to keep growing.

Foolish takeaway

I would not necessarily expect these ASX shares to outperform every year.

What I like is that each company has a strong position today and a clear opportunity to become much larger over the next decade.

If I could buy Pro Medicus, TechnologyOne, and REA Group at sensible valuations, I would be happy to hold them for years and give those growth stories time to develop.

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Smiling woman taking a video through a plane window with her phone.
Growth Shares

2 ASX growth shares tipped to return 20% to 77%

One offers the steadier growth story, while the other could deliver much greater upside if execution improves.

Read more »

Young couple having pizza on lunch break at workplace.
Growth Shares

3 ASX growth shares experts think could double

Three beaten-up names, three very bullish targets.

Read more »

Man smiling ahead while working on his MacBook.
Growth Shares

Top 3 ASX 200 shares to buy in September

There are good reasons these shares could be top picks today.

Read more »

Buy and sell keys on an Apple keyboard.
Growth Shares

Why a fund manager loves these ASX shares right now

These stocks could be compelling buys today…

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Growth Shares

2 top ASX shares to buy and hold for the next decade

These stocks could deliver excellent long-term returns…

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Growth Shares

Why I'd invest $10,000 into these ASX growth shares

The recent falls have made these two high-growth technology businesses much more interesting to me at today’s prices.

Read more »

Happy businessman fist pumping while looking at a tablet.
Growth Shares

Where I'd invest $15,000 in ASX shares now

I think these three businesses can keep finding new ways to become much larger over the years ahead.

Read more »

A kangaroo stands on a sandy beach with vivid white sand and blue sea in the background
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

This business is heavily undervalued, in my opinion.

Read more »